A Phase 1/2 Open Label Study to Evaluate the Safety and Efficacy of CT071, an Autologous Anti-GPRC5D CAR T, in Relapsed/Refractory Multiple Myeloma (RRMM) or Relapsed/Refractory Primary Plasma Cell Leukemia (RRpPCL)
Latest Information Update: 01 Apr 2024
At a glance
- Drugs CT-071 (Primary)
- Indications Multiple myeloma; Plasma cell leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors CARsgen
- 01 Apr 2024 New trial record